A global study led by a Royal Veterinary College professor has shown clear evidence of the benefit of pimobendan in dogs with mitral valve disease.
The prospective double-blind, randomised, placebo-controlled clinical trial evaluated the effectiveness of pimobendan in the prevention of the onset of signs of congestive heart failure in dogs with cardiac enlargement secondary to pre-clinical myxomatous mitral valve disease.
It was ended on March 1, 2015 with the unanimous agreement of the lead investigators – Prof Boswood, Sonya Gordon and Jens Häggström – following the advice of an independent interim analysis committee.
The interim analysis was conducted with a number of pre-specified stopping criteria, agreed in consultation with an independent statistical consultant, and was concluded on February 16.
It indicated there was clear evidence of benefit of the administration of pimobendan in prolonging the time to the primary endpoint of the study, which was a composite of the development of left-sided congestive heart failure, or death presumed to be cardiac in origin.
The analysis did not raise any concern over the safety of pimobendan administration.
The full and final results of the study are expected at a later date.